Vincent Guiraud

Dr. Vincent Guiraud


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2025 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
RDRemy Dulery
Remy Dulery
VGVincent Guiraud
Vincent Guiraud
SCSylvain Choquet
Sylvain Choquet
CTCatherine Thieblemont
Catherine Thieblemont
EBEmmanuel Bachy
Emmanuel Bachy
RHRoch Houot
Roch Houot

17 July 2023 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
VGVincent Guiraud
Vincent Guiraud
JBJonathan Bocobza
Jonathan Bocobza
MDMarion Desmonet
Marion Desmonet
FDFlorence Damond
Florence Damond
JPJean-Christophe Plantier
Jean-Christophe Plantier
AGAgnès Gautheret-Dejean
Agnès Gautheret-Dejean
Immunoblots remain the gold standard for HIV-1/HIV-2 infection confirmation. However, their ability to differentiate HIV-1 from HIV-2 infection on an antigenically diversified HIV-1 and HIV-2 panel remain uncommon.

14 April 2023 in Journal of Clinical Virology
Verified
Journal Article
Closed access
VGVincent Guiraud
Vincent Guiraud
FCFlorian Crémoux
Florian Crémoux
ILIsabelle Leroy
Isabelle Leroy
JCJulien Cohier
Julien Cohier
PHPierre Hernandez
Pierre Hernandez
AGAgnès Gautheret-Dejean
Agnès Gautheret-Dejean

8 May 2024 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
VGVincent Guiraud
Vincent Guiraud
YCYann Ciczora
Yann Ciczora
MCMuriel Cardona
Muriel Cardona
CDChristine Defer
Christine Defer
SGSandrine Gréaume
Sandrine Gréaume
AGAgnès Gautheret-Dejean
Agnès Gautheret-Dejean
Diagnosing of human immunodeficiency virus (HIV) types 1 and 2 requires a screening with a highly sensitive and specific enzyme immunoassay and a low detection limit for the HIV-1 p24 antigen to minimize the diagnostic window. The objective of the study was to determine the sensitivity, specificity, and p24 limit of detection of the Access HIV combo V2 assay. Retrospective part of sensitivity: 452 HIV-1 positive samples from 403 chronic (9 different HIV-1 group M subtypes, 22 different HIV-1 group M CRFs, and 3 HIV-1 group O), 49 primary HIV-1 infections, 103 HIV-2 positive samples assessed at Pitié-Salpêtrière Hospital, 600 untyped HIV-1, 10 subtype-D, and 159 untyped HIV-2 samples assessed in Bio-Rad Laboratories. Prospective part of clinical specificity: all consecutive samples in two blood donor facilities and Pitié-Salpêtrière (6,570 patients) tested with Access HIV combo V2 and respectively Prism HIV O Plus (Abbott) or Architect HIV Ag/Ab Combo (Abbott) for Ag/Ab screening, and Procleix Ultrio (Gen Probe) for HIV RNA screening. Limit of detection for p24 antigen was assessed on recombinant virus-like particles (10 HIV-1 group M subtypes/CRFs, HIV-1 group O). Sensitivity [95% confidence interval (CI)] of Access HIV combo V2 was 100% (99.63–100) for HIV-1 chronic infection, 100% (98.55–100) for HIV-2 chronic infection, and 100% (93.00–100) for HIV-1 primary infection. Specificity (95% CI) was 99.98 (99.91–100). Limit of detection for p24 antigen was around 0.43 IU/mL [interquartile range (0.38–0.56)], and consistent across the 11 analyzed subtypes/CRFs. Hence, with both high sensitivity and specificity, Access HIV combo V2 is a suitable screening assay for HIV-1/2 infection. IMPORTANCE: Bio-Rad is one of the leading human immunodeficiency virus (HIV) screening test manufacturers. This laboratory released in 2021 their new version of the Access combo HIV test. However, to date, there have been no studies regarding its performance, especially its limit of detection of the diverse p24 antigen. We present the sensitivity (chronic and primary HIV-1 infection and HIV-2 chronic infection), specificity (blood donors and hospitalized patients), and raw data for the p24/seroconversion panels the manufacturer gave to the European agencies.

19 February 2025 in British Journal of Haematology
Verified
Journal Article
Open access
VGVincent Guiraud
Vincent Guiraud
Jérôme DENISJérôme DENIS
Jérôme DENIS
GBGhizlane Benhafoun
Ghizlane Benhafoun
EAErwan Ablin
Erwan Ablin
SSSophie Sayon
Sophie Sayon
ETEve Todesco
Eve Todesco
Summary: T‐cell malignancies following chimeric antigen receptor (CAR) therapies are partly related to insertional mutagenesis, but the longitudinal evolution of CAR‐integration sites (IS) remains understudied. We performed an IS analysis in blood from three tisagenlecleucel (lentiviral), one axicabtagene‐ciloleucel and one brexucabtagene‐autoleucel (gammaretrovirals) patient at peak expansion and 1‐year follow‐up. All were complete responders. Peak expansion IS patterns were vector dependent: lentiviral CAR integrated mostly in introns and gammaretrovirals in intergenic regions, closer to transcription start sites. At 1‐year post‐infusion, lentiviral CAR showed no major clonal proliferation. Gammaretroviral CARs had divergent outcomes: no detectable CAR (axicabtagene‐ciloleucel) or low‐level oligoclonal persistence (brexucabtagene‐autoleucel). Whether this latter evolution is at risk of further CAR malignancies needs further investigations.

16 February 2025 in Infectious Diseases Now
Verified
Journal Article
Open access
VGVincent Guiraud
Vincent Guiraud
DSDelphine Sauce
Delphine Sauce
RBRanda Bittar
Randa Bittar
JFJosé Fernandez
José Fernandez
HTHenri Thévenet
Henri Thévenet
VPValérie Pourcher
Valérie Pourcher
Positive cardiovascular and renal outcomes associated with the sodium-glucose cotransporter 2 inhibitor (SGLT2i) use are attributed to their anti-inflammatory properties. Persistent immune activation accounts for part of the elevated cardiovascular risk of people living with HIV (PWH), but SGLT2i impact on this population has been poorly described. All PWH with a history of SGLT2i treatment from May 2020 to April 2023 receiving care at Pitié-Salpêtrière Hospital (Paris, France) and with available pre- and post-treatment blood samples were included. Clinical and biological data were extracted from medical records, metabolic and immune biomarkers from cryopreserved plasma samples. Most of the 20 patients with SGLT2i treatment were men (75 %), with a median [IQR] age of 59 years [55;68], receiving antiretroviral therapy for a median of 21.5 years [15.3;26.5]. Most had type 2 diabetes (95 %), chronic kidney disease (90 %), dyslipidemia (80 %), and hypertension (75 %). SGLT2i treatment was associated with a median weight loss of 3 kg, an increase in hematocrit, and decreased AST levels. LDL, HDL, oxLDL, and Lp-PLA2 levels were unaffected. SGLT2i was associated with inflammasome inhibition and with decreased circulating levels of IL-1β and IL-8. We also observed a decrease in cytokines associated with the recruitment and activation of monocytes-macrophages MCP-1, MIP-1α, MIP-1β, Eotaxin, RANTES, IL-8, and their positive feedback, IL-13/IL-4. Decreased IL-6, CRP, and sCD14 levels were not significant. SGLT2i was associated with weight loss and a significant impact on innate immunity in PWH, with inhibition of inflammasome and monocyte-macrophage activation.